PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men with negative or inconclusive MRI findings but persistent clinical risk factors. According to new research published in The Journal of Nuclear Medicine, combining the two biopsy approaches is even more effective, nearly doubling the detection rate. This strategy may help physicians identify clinically significant cancers that would otherwise be difficult to detect, while potentially avoiding unnecessary procedures in appropriately selected patients.